Evidence map›Paper›PMID 24330607›Full record

ArticleBMC cancer2013

High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.

Gregor Auf, Arnaud Jabouille, Maylis Delugin, Sylvaine Guérit, Raphael Pineau, Sophie North, Natalia Platonova, Marlène Maitre, Alexandre Favereaux, Peter Vajkoczy and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 107 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. The Role of EREG/EGFR Pathway in Tumor Progression.International journal of molecular sciences · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Gregor Auf
Arnaud Jabouille
Maylis Delugin
Sylvaine Guérit
Raphael Pineau
Sophie North
Natalia Platonova
Marlène Maitre
Alexandre Favereaux
Peter Vajkoczy
Masaharu Seno
Andreas Bikfalvi
Dmitri Minchenko
Oleksandr MinchenkoInserm, LAMC, UMR 1029, Talence F-33400, France. ominchenko@yahoo.com.
Michel Moenner
Université de Bordeaux · FRInserm · FRPalladin Institute of Biochemistry · UACentre National de la Recherche Scientifique · FRCharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidermal growth factor (EGF) receptors contribute to the development of malignant glioma. Here we considered the possible implication of the EGFR ligand epiregulin (EREG) in glioma development in relation to the activity of the unfolded protein response (UPR) sensor IRE1α. We also examined EREG status in several glioblastoma cell lines and in malignant glioma.

methodsExpression and biological properties of EREG were analyzed in human glioma cells in vitro and in human tumor xenografts with regard to the presence of ErbB proteins and to the blockade of IRE1α. Inactivation of IRE1α was achieved by using either the dominant-negative strategy or siRNA-mediated knockdown.

resultsEREG was secreted in high amounts by U87 cells, which also expressed its cognate EGF receptor (ErbB1). A stimulatory autocrine loop mediated by EREG was evidenced by the decrease in cell proliferation using specific blocking antibodies directed against either ErbB1 (cetuximab) or EREG itself. In comparison, anti-ErbB2 antibodies (trastuzumab) had no significant effect. Inhibition of IRE1α dramatically reduced EREG expression both in cell culture and in human xenograft tumor models. The high-expression rate of EREG in U87 cells was therefore linked to IRE1α, although being modestly affected by chemical inducers of the endoplasmic reticulum stress. In addition, IRE1-mediated production of EREG did not depend on IRE1 RNase domain, as neither the selective dominant-negative invalidation of the RNase activity (IRE1 kinase active) nor the siRNA-mediated knockdown of XBP1 had significant effect on EREG expression. Finally, chemical inhibition of c-Jun N-terminal kinases (JNK) using the SP600125 compound reduced the ability of cells to express EREG, demonstrating a link between the growth factor production and JNK activation under the dependence of IRE1α.

conclusionEREG may contribute to glioma progression under the control of IRE1α, as exemplified here by the autocrine proliferation loop mediated in U87 cells by the growth factor through ErbB1.

Indexed as

AnimalsAnthracenesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAutocrine CommunicationBrain NeoplasmsCell Line, TumorCell MovementCell ProliferationCetuximabEndoribonucleasesEpidermal Growth FactorEpiregulinErbB ReceptorsGene ExpressionGliomaAnthracenesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabEndoribonucleasesEpidermal Growth FactorEpiregulinErbB ReceptorsEREG protein, humanEreg protein, mouseERN1 protein, humanJNK Mitogen-Activated Protein KinasesProtein Serine-Threonine Kinasespyrazolanthrone

Identifiers

PMID24330607
PMCPMC3878670
OpenAlexW2071478517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.